Production and Purification of Recombinant Adeno-Associated Vectors

Methods in Molecular Biology

Volumn 807, Issue , 2011, Pages 361-404

  Wang, Lijun ^a   Blouin, Véronique ^b   Brument, Nicole ^b   Bello Roufai, Mahajoub ^a   Francois, Achille ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Adeno associated virus; cGMP; Clinical trial; Gene therapy; Production; Purification; rAAV; Vector

Indexed keywords

ADENO ASSOCIATED VIRUS; ANIMAL; BIOSYNTHESIS; GENE THERAPY; GENE VECTOR; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; REVIEW;

ANIMALS; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS;

EID: 83455225589     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-370-7_16     Document Type: Chapter

References (74)

1. McLaughlin, S. K., Collis, P., Hermonat, P. L., and Muzyczka, N. (1988) Adeno-associated virus general transduction vectors: analysis of proviral structures, J Virol 62, 1963–1973.
2. Salvetti, A., Oreve, S., Chadeuf, G., Favre, D., Cherel, Y., Champion-Arnaud, P., David-Ameline, J., and Moullier, P. (1998) Factors influencing recombinant adeno-associated virus production, Hum Gene Ther 9, 695–706.
3. Merten, O. W., Geny-Fiamma, C., and Douar, A. M. (2005) Current issues in adeno-associated viral vector production, Gene Ther 12 Suppl 1, S51-61.
4. Aucoin, M. G., Perrier, M., and Kamen, A. A. (2008) Critical assessment of current adeno-associated viral vector production and quantification methods, Biotechnol Adv 26, 73–88.
5. Urabe, M., Ding, C., and Kotin, R. M. (2002) Insect cells as a factory to produce adeno-associated virus type 2 vectors, Hum Gene Ther 13, 1935–1943.
6. Smith, R. H., Levy, J. R., and Kotin, R. M. (2009) A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells, Mol Ther 17, 1888–1896.
7. Aslanidi, G., Lamb, K., and Zolotukhin, S. (2009) An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells, Proc Natl Acad Sci U S A 106, 5059–5064.
8. Xiao, X., Li, J., and Samulski, R. J. (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus, J Virol 72, 2224–2232.
9. Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R. J. (2002) Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity, J Virol 76, 791–801.
10. Grimm, D., Kern, A., Rittner, K., and Kleinschmidt, J. A. (1998) Novel tools for production and purification of recombinant adenoassociated virus vectors, Hum Gene Ther 9, 2745–2760.
11. Collaco, R. F., Cao, X., and Trempe, J. P. (1999) A helper virus-free packaging system for recombinant adeno-associated virus vectors, Gene 238, 397–405.
12. Grimm, D., Kay, M. A., and Kleinschmidt, J. A. (2003) Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6, Mol Ther 7, 839–850.
13. Gao, G. P., Qu, G., Faust, L. Z., Engdahl, R. K., Xiao, W., Hughes, J. V., Zoltick, P. W., and Wilson, J. M. (1998) High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus, Hum Gene Ther 9, 2353–2362.
14. Liu, X. L., Clark, K. R., and Johnson, P. R. (1999) Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus, Gene Ther 6, 293–299.
15. Zhang, H., Xie, J., Xie, Q., Wilson, J. M., and Gao, G. (2009) Adenovirus-adeno-associated virus hybrid for large-scale recombinant adeno-associated virus production, Hum Gene Ther 20, 922–929.
16. Clark, K. R., Voulgaropoulou, F., Fraley, D. M., and Johnson, P. R. (1995) Cell lines for the production of recombinant adeno-associated virus, Hum Gene Ther 6, 1329–1341.
17. Blouin, V., Brument, N., Toublanc, E., Raimbaud, I., Moullier, P., and Salvetti, A. (2004) Improving rAAV production and purification: towards the definition of a scaleable process, J Gene Med 6 Suppl 1, S223-228.
18. Thorne, B. A., Takeya, R. K., and Peluso, R. W. (2009) Manufacturing recombinant adeno-associated viral vectors from producer cell clones, Hum Gene Ther 20, 707–714.
19. Toublanc, E., Benraiss, A., Bonnin, D., Blouin, V., Brument, N., Cartier, N., Epstein, A. L., Moullier, P., and Salvetti, A. (2004) Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines, J Gene Med 6, 555–564.
20. Gao, G. P., Lu, F., Sanmiguel, J. C., Tran, P. T., Abbas, Z., Lynd, K. S., Marsh, J., Spinner, N. B., and Wilson, J. M. (2002) Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap, Mol Ther 5, 644–649.
21. Farson, D., Harding, T. C., Tao, L., Liu, J., Powell, S., Vimal, V., Yendluri, S., Koprivnikar, K., Ho, K., Twitty, C., Husak, P., Lin, A., Snyder, R. O., and Donahue, B. A. (2004) Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors, J Gene Med 6, 1369–1381.
22. Conway, J. E., Rhys, C. M., Zolotukhin, I., Zolotukhin, S., Muzyczka, N., Hayward, G. S., and Byrne, B. J. (1999) High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap, Gene Ther 6, 986–993.
23. Kang, W., Wang, L., Harrell, H., Liu, J., Thomas, D. L., Mayfield, T. L., Scotti, M. M., Ye, G. J., Veres, G., and Knop, D. R. (2009) An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes, Gene Ther 16, 229–239.
24. Booth, M. J., Mistry, A., Li, X., Thrasher, A., and Coffin, R. S. (2004) Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids, Gene Ther 11, 829–837.
25. Negrete, A., and Kotin, R. M. (2008) Large-scale production of recombinant adeno-associated viral vectors, Methods Mol Biol 433, 79–96.
26. Negrete, A., and Kotin, R. M. (2007) Production of recombinant adeno-associated vectors using two bioreactor configurations at different scales, J Virol Methods 145, 155–161.
27. Cecchini, S., Virag, T., Negrete, A., and Kotin, R. M. (2009) Production and Processing of rAAVU7smOPT in 100L Bioreactors for Canine Models of Duchenne Muscular Dystrophy, Mol Ther 17, 17.
28. Durocher, Y., Pham, P. L., St-Laurent, G., Jacob, D., Cass, B., Chahal, P., Lau, C. J., Nalbantoglu, J., and Kamen, A. (2007) Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells, J Virol Methods 144, 32–40.
29. Hauck, B., Qu, G., Zelenaia, O., Zhou, J., Liu, X., Africa, L., High, K. A., and Wright, J. F. (2009) A Scalable Manufacturing Platform for Purification of AAV Serotypes 2, 5, 6 and 8 for IND-Supporting Pre-Clinical Studies and Clinical Trials, Mol Ther 17, S17.
30. Thomas, D. L., Wang, L., Niamke, J., Liu, J., Kang, W., Scotti, M. M., Ye, G. J., Veres, G., and Knop, D. R. (2009) Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells, Hum Gene Ther 20, 861–870.
31. Zeltner, N., Kohlbrenner, E., Clément, N., Weber, T., and Linden, R. M. (2010) Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors., Gene Ther 17.
32. Ayuso, E., Mingozzi, F., Montane, J., Leon, X., Anguela, X. M., Haurigot, V., Edmonson, S. A., Africa, L., Zhou, S., High, K. A., Bosch, F., and Wright, J. F. (2009) High AAV vector purity results in serotype-and tissue-indepen-dent enhancement of transduction efficiency, Gene Ther.
33. Wright, J. F. (2009) Transient transfection methods for clinical adeno-associated viral vector production, Hum Gene Ther 20, 698–706.
34. Knop, D. R., and Harrell, H. (2007) Bioreactor production of recombinant herpes simplex virus vectors, Biotechnol Prog 23, 715–721.
35. Virag, T., Cecchini, S., and Kotin, R. M. (2009) Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy, Hum Gene Ther 20, 807–817.
36. Pijlman, G. P., van Schijndel, J. E., and Vlak, J. M. (2003) Spontaneous excision of BAC vector sequences from bacmid-derived baculovirus expression vectors upon passage in insect cells, J Gen Virol 84, 2669–2678.
37. Edelstein, M. L., Abedi, M. R., and Wixon, J. (2007) Gene therapy clinical trials worldwide to 2007--an update, J Gene Med 9, 833–842.
38. Gao, G., Qu, G., Burnham, M. S., Huang, J., Chirmule, N., Joshi, B., Yu, Q. C., Marsh, J. A., Conceicao, C. M., and Wilson, J. M. (2000) Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo, Hum Gene Ther 11, 2079–2091.
39. O’Riordan, C. R., Lachapelle, A. L., Vincent, K. A., and Wadsworth, S. C. (2000) Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV), J Gene Med 2, 444–454.
40. Brument, N., Morenweiser, R., Blouin, V., Toublanc, E., Raimbaud, I., Cherel, Y., Folliot, S., Gaden, F., Boulanger, P., Kroner-Lux, G., Moullier, P., Rolling, F., and Salvetti, A. (2002) A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and −5, Mol Ther 6, 678–686.
41. Kaludov, N., Handelman, B., and Chiorini, J. A. (2002) Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography, Hum Gene Ther 13, 1235–1243.
42. Davidoff, A. M., Ng, C. Y., Sleep, S., Gray, J., Azam, S., Zhao, Y., McIntosh, J. H., Karimipoor, M., and Nathwani, A. C. (2004) Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock, J Virol Methods 121, 209–215.
43. Smith, R. H., Ding, C., and Kotin, R. M. (2003) Serum-free production and column purification of adeno-associated virus type 5, J Virol Methods 114, 115–124.
44. Chahal, P. S., Aucoin, M. G., and Kamen, A. (2007) Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system, J Virol Methods 139, 61–70.
45. Qu, G., Bahr-Davidson, J., Prado, J., Tai, A., Cataniag, F., McDonnell, J., Zhou, J., Hauck, B., Luna, J., Sommer, J. M., Smith, P., Zhou, S., Colosi, P., High, K. A., Pierce, G. F., and Wright, J. F. (2007) Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography, J Virol Methods 140, 183–192.
46. Urabe, M., Xin, K. Q., Obara, Y., Nakakura, T., Mizukami, H., Kume, A., Okuda, K., and Ozawa, K. (2006) Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression, Mol Ther 13, 823–828.
47. Tamayose, K., Hirai, Y., and Shimada, T. (1996) A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography, Hum Gene Ther 7, 507–513.
48. Francis, J. D. a. S., R.O. (2005) Production of Research and Clinical Grade Recombinant Adeno-associated Viral Vectors., Vol. 31, Elsevier, Amsterdam.
49. Okada, T., Nonaka-Sarukawa, M., Uchibori, R., Kinoshita, K., Hayashita-Kinoh, H., Nitahara-Kasahara, Y., Takeda, S., and Ozawa, K. (2009) Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes, Hum Gene Ther 20, 1013–1021.
50. Auricchio, A., Hildinger, M., O’Connor, E., Gao, G. P., and Wilson, J. M. (2001) Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column, Hum Gene Ther 12, 71–76.
51. Snyder, R. O., and Flotte, T. R. (2002) Production of clinical-grade recombinant adeno-associated virus vectors, Curr Opin Biotechnol 13, 418–423.
52. Clark, K. R., Liu, X., McGrath, J. P., and Johnson, P. R. (1999) Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses, Hum Gene Ther 10, 1031–1039.
53. Anderson, R., Macdonald, I., Corbett, T., Whiteway, A., and Prentice, H. G. (2000) A method for the preparation of highly purified adeno-associated virus using affinity column chromatography, protease digestion and solvent extraction, J Virol Methods 85, 23–34.
54. Auricchio, A., O’Connor, E., Hildinger, M., and Wilson, J. M. (2001) A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors, Mol Ther 4, 372–374.
55. Cecchini, S., Negrete, A., and Kotin, R. M. (2008) Toward exascale production of recombinant adeno-associated virus for gene transfer applications, Gene Ther 15, 823–830.
56. Wang, L., and Knop, D. R. (2007) Affinity Chromatography Purification of rAAV Vectors Produced by Transfection or rHSV Co-infection Using CaptureSelect AAV ligand, Mol Ther 15 .
57. Wang, L., Niamke, J., Veres, G., and Knop, D. (2008) Two-Step Scalable Purification Process of rAAV1 Vectors Produced by rHSV Co-Infection in Suspension BHK Cells, Mol Ther 16, 291.
58. Wang, L., Veres, G., and Knop, D. R. (2009) Two-step Chromatography Purification of rAAV1 Vectors produced by Suspension BHK Cells rHSV Co-infection, Mol Ther 17, 715.
59. Arnold, G. S., Sasser, A. K., Stachler, M. D., and Bartlett, J. S. (2006) Metabolic biotinyla-tion provides a unique platform for the purification and targeting of multiple AAV vector serotypes, Mol Ther 14, 97–106.
60. Stachler, M. D., and Bartlett, J. S. (2006) Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells, Gene Ther 13, 926–931.
61. Koerber, J. T., Jang, J. H., Yu, J. H., Kane, R. S., and Schaffer, D. V. (2007) Engineering adeno-associated virus for one-step purification via immobilized metal affinity chromatography, Hum Gene Ther 18, 367–378.
62. Smith, R. H., Yang, L., and Kotin, R. M. (2008) Chromatography-based purification of adeno-associated virus, Methods Mol Biol 434, 37–54.
63. Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., and Muzyczka, N. (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield, Gene Ther 6, 973–985.
64. Summerford, C., and Samulski, R. J. (1998) Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions, J Virol 72, 1438–1445.
65. Mizukami, H., Young, N. S., and Brown, K. E. (1996) Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein, Virology 217, 124–130.
66. Qiu, J., Handa, A., Kirby, M., and Brown, K. E. (2000) The interaction of heparin sulfate and adeno-associated virus 2, Virology 269, 137–147.
67. Kaludov, N., Brown, K. E., Walters, R. W., Zabner, J., and Chiorini, J. A. (2001) Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemaggluti-nation and efficient transduction but differ in sialic acid linkage specificity, J Virol 75, 6884–6893.
68. Snyder, R. O., and Francis, J. (2005) Adeno-associated viral vectors for clinical gene transfer studies, Curr Gene Ther 5, 311–321.
69. Mandel, R. J., Burger, C., and Snyder, R. O. (2008) Viral vectors for in vivo gene transfer in Parkinson’s disease: properties and clinical grade production, Exp Neurol 209, 58–71.
70. Chadeuf, G., Favre, D., Tessier, J., Provost, N., Nony, P., Kleinschmidt, J., Moullier, P., and Salvetti, A. (2000) Ef ficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome, J Gene Med 2, 260–268.
71. Mathews, L. C., Gray, J.T., Gallagher, M.R., and Snyder, R.O. (2002) Recombinant Adeno-associated Viral Vector Production Using Stable Packaging and Producer Cell Lines., in Methods in Enzymology, pp 393–413.
72. Nony, P., Chadeuf, G., Tessier, J., Moullier, P., and Salvetti, A. (2003) Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles, J Virol 77, 776–781.
73. Francois, A., Guilbaud, M., Awedikian, R., Chadeuf, G., Moullier, P., and Salvetti, A. (2005) The cellular TATA binding protein is required for rep-dependent replication of a minimal adeno-associated virus type 2 p5 element, J Virol 79, 11082–11094.
74. Rice, S. A., and Knipe, D. M. (1990) Genetic evidence for two distinct transactivation functions of the herpes simplex virus alpha protein ICP27, J Virol 64, 1704–1715.